Of note, while decreased -median (range)- counts in blood of cMo in SMM were (exclusively) at the expense of CD62L+ cMo −141 (53–518) cells/μL vs. 230 (69–732) cells/μL in HD (p = 0.004)-, in symptomatic MM all subsets of cMo were significantly decreased vs. HD, including CD62L+ cMo −153 (59–476) cells/μL vs. 230 (69–732) cells/μL, respectively (p = 0.02)-, CD62L− cMo −32 (4–131) cells/μL vs. 51 (9–189) cells/μL, respectively (p = 0.02)- and particularly, FcεRI+ cMo −1.4 (0.4–33) cells/μL vs. 30 (3–125) cells/μL, respectively (p = 0.001)- (Figure 3C–E). This evidence concerns the gene SELL and Miyoshi myopathy.